The PGE2-Stat3 interaction in doxorubicin-induced myocardial apoptosis

Cardiovascular Research

Volumn 80, Issue 1, 2008, Pages 69-77

  Frias, Miguel A ^a   Somers, Sarin ^b   Gerber Wicht, Christine ^a   Opie, Lionel H ^b   Lecour, Sandrine ^b   Lang, Ursula ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

Apoptosis; Prostaglandins; Signal transduction

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 16,16 DIMETHYLPROSTAGLANDIN E2; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; CASPASE 3; DOXORUBICIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; N BENZYL 2 CYANO 3 (3,4 DIHYDROXYPHENYL)ACRYLAMIDE; PROSTAGLANDIN E2; SMALL INTERFERING RNA; STAT3 PROTEIN; ANTINEOPLASTIC ANTIBIOTIC; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN, RAT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOTOXICITY; CELL VIABILITY; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVATION; GENETIC TRANSFECTION; HEART MUSCLE; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; KNOCKOUT MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RAT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; METABOLISM; MOUSE; MOUSE MUTANT; WISTAR RAT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL SURVIVAL; CELLS, CULTURED; DINOPROSTONE; DOXORUBICIN; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; MICE; MICE, KNOCKOUT; MYOCYTES, CARDIAC; RATS; RATS, WISTAR; STAT3 TRANSCRIPTION FACTOR;

EID: 51749083547     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvn171     Document Type: Article

References (42)

1. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998;339:900-905.
2. Takemura G, Fujiwara H. Doxorubicin-induced cardiomyopathy from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 2007;49:330-352.
3. Keizer HG, Pinedo HM, Schuuruis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther 1990;47:219-231.
4. Singal PK, Li T, Kumar D, Danelisen D, Iliskovic N. Adriamycin-induced heart failure: mechanism and modulation. Mol Cell Biochem 2000;207:77-86.
5. Iliskovic N, Singal PK. Lipid lowering: an important factor in preventing adriamycin-induced heart failure. Am J Pathol 1997;150:727-734.
6. Siveski-Iliskovic N, Kaul N, Singal PK. Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 1994;89:2829-2835.
7. Childs AC, Phaneuf SL, Dirks AJ, Phillips T, Leeuwenburgh C. Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2:Bax ratio. Cancer Res 2002;62:4592-4598.
8. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004;23:7018-7030.
9. Adderley SR, Fitzgerald DJ. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinase 1/2-mediated induction of cyclooxygenase-2. J Biol Chem 1999;274:5038-5046.
10. Dowd NP, Scully M, Adderley SR, Cunningham AJ, Fitzgerald DJ. Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 2001;108:585-590.
11. Neilan TG, Doherty GA, Chen G, Deflandre C, McAllister H, Butler RK et al. Disruption of COX-2 modulates gene expression and the cardiac injury response to doxorubicin. Am J Physiol Heart Circ Physiol 2006;291:H532-H536.
12. Camitta MG, Gabel SA, Chulada P, Bradbury JA, Langenbach R, Zeldin DC et al. Cyclooxygenase-1 and -2 knockout mice demonstrate increased cardiac ischemia/reperfusion injury but are protected by acute preconditioning. Circulation 2001;104:2453-2458.
13. Xiao CY, Yuhki K, Hara A, Fujino T, Kuriyama S, Yamada Tet al. Prostaglandin E2 protects the heart from ischemia-reperfusion injury via its receptor subtype EP4. Circulation 2004;109:2462-2468.
14. Martin M, Kaber G, Jacoby C, Flogel U, Schrader J, Schror K et al. Cardiospecific overexpression of the prostaglandin EP3 receptor attenuates ischemia-induced myocardial injury. Circulation 2005;112:400-406.
15. Xuan YT, Guo Y, Zhu Y, Han H, Langenbach R, Dawn B et al. Mechanism of cyclooxygenase-2 upregulation in late preconditioning. J Mol Cell Cardiol 2003;35:525-537.
16. Zhao ZQ. Oxidative stress-elicited myocardial apoptosis during reperfusion. Curr Opin Pharmacol 2004;4:159-165.
17. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B et al. Pharmacological preconditioning with tumor necrosis factor-alpha activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005;112:3911-3918.
18. Hilfiker-Kleiner D, Hilfiker A, Fuchs M, Kaminski K, Schaefer A, Schieffer B et al. Signal transducer and activator of transcription 3 is required for myocardial capillary growth, control of interstitial matrix deposition, and heart protection from ischemic injury. Circ Res 2004;95:187-195.
19. Hilfiker-Kleiner D, Hilfiker A, Drexler H. Many good reasons to have STAT3 in the heart. Pharmacol Ther 2005;107:131-137.
20. Negoro S, Kunisada K, Tone E, Funamoto M, Oh H, Kishimoto T et al. Activation of JAK/STAT pathway transduces cytoprotective signal in rat acute myocardial infarction. Cardiovasc Res 2000;47:797-805.
21. Negoro S, Kunisada, Fujio Y, Funamoto M, Darville MI, Eizirik DL et al. Activation of signal transducer and activator of transcription 3 protects cardiomyocytes from hypoxia/reoxigenation-induced oxidative stress through the upregulation of manganese superoxide dismutase. Circulation 2001;104:979-981.
22. Jacoby JJ, Kalinowski A, Liu MG, Zhang SSM, Gao Q, Chai GX et al. Cardiomyocyte-restricted knockout of STAT3 results in higher sensitivity to inflammation, cardiac fibrosis, and heart failure with advanced age. Proc Natl Acad Sci USA 2003;100:12929-12934.
23. Kunisada K, Negoro S, Tone E, Funamoto M, Yamauchi-Takihara K. Signal transducer and activator of transcription 3 in the heart transduces not only a hypertrophic signal but a protective signal against doxorubicin-induced cardiomyopathy. Proc Natl Acad Sci USA 2000;97:315-319.
24. Frias MA, Rebsamen MC, Gerber-Wicht C, Lang U. Prostaglandin E2 activates Stat3 in neonatal rat ventricular cardiomyocytes: A role in cardiac hypertrophy. Cardiovasc Res 2007;73:57-65.
25. Smith RM, Suleman N, Lacerda L, Opie LH, Akira S, Chien KR et al. Genetic depletion of cardiac myocyte STAT-3 abolishes classical preconditioning. Cardiovasc Res 2004;63:611-616.
26. Hansen-Petrik MB, McEntee MF, Jull B, Shi H, Zemel MB, Whelan J. Prostaglandin E2 protect intestinal tumors from nonsteroidal antiinflammatory drug-induced regression in APCMin/+ Mice. Cancer Res 2002;62:403- 408.
27. Wilson JW, Potten CS. The effect of exogenous prostaglandin administration on tumor size and yield in Min/+ mice. Cancer Res 2000;60:4645-4653.
28. Davies SP, Reddy H, Caivano M, Cohen P. Specifity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000;351:95-105.
29. Jiang Y, Gram H, Zhao M, New L, Gu J, Feng L et al. Characterization of the structure and function of the fourth member of p38 group mitogen-activated protein kinase p38d. J Biol Chem 1997;272: 30122-30128.
30. Lee JC, Kassis S, Kumar S, Badger A, Adams JL. P38 Mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials. Pharmacol Ther 1999;82:389-397.
31. Meydan N, Grunberger T, Dadi H, Shaha M, Arpaia E, Lapidot Z et al. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 1997;379:645-648.
32. Su I, David M. Distinct mechanisms of Stat phosphorylation via the interferon-α/β receptor. Selective inhibition of Stat3 and Stat5 by piceatannol. J Biol Chem 2000;275:12661-12666.
33. Opie LH, Commerford PJ, Gerh BJ, Pfeffer MA. Controversies in ventricular remodelling. Lancet 2006;367:356-367.
34. Sugden PH. Mechanotransduction in cardiomyocyte hypertrophy. Circulation 2001;103:1375-1377.
35. Baines CP, Molkentin JD. STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol 2005;38:47-62.
36. Rebsamen MC, Perrier E, Gerber-Wicht C, Benitah JP, Lang U. Direct and indirect effects of aldosterone on COX-2 and IL-6 expression in rat cardiac cells in culture and after myocardial infarction. Endocrinoloyg 2004;145:3135-3142.
37. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am J Physiol Heart Circ Physiol 2004;286:H1416-H1424.
38. Qian JY, Harding P, Liu Y, Shesely E, Yang XP, LaPointe MC. Reduced cardiac remodeling and function in cardiac-specific EP4 receptor knockout mice with myocardial infarction. Hypertension 2008;51:560-566.
39. Boengler K, Buechet A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G et al. Cardioprotection by ischemic postconditioning is lost in aged and Stat3-deficient mice. Circ Res 2008;102:131-135.
40. Delgado RM, Nawar MA, Zewail AM, Kar B, Vaughn WK, Wu KK et al. Cyclooxygenase-2 inhibitor treatment improves left ventricular function and mortality in a murine model of doxorubicin-induced heart failure. Circulation 2004;109:1428-1433.
41. Bouchard J-F, Chouinard J, Lamontagne D. Participation of prostaglandin E2 in the endothelial protective effect of ischaemic preconditioning in isolated rat heart. Cardiovasc Res 2000;45:418-427.
42. Zhu W, Zou Y, Aikawa R, Harada K, Kudoh S, Uozumi H et al. MAPK super-family plays an important role in daunomycin-induced apoptosis of cardiac myocytes. Circulation 1999;100:2100-2107.